Application

Anti-Dopamine Transporter, clone 1D2 ZooMAb, Cat. No. ZRB1525, is a recombinant Rabbit monoclonal antibody that targets Dopamine Transporter (DAT) and is tested Affinity Binding Assay, Immunohistochemistry (Paraffin), and Western Blotting.

Immunohistochemistry (Paraffin) Analysis: A 1:100 dilution from a representative lot detected Dopamine Transporter in mouse brain and rat brain tissue sections.Affinity Binding Assay: A representative lot of this antibody bound human Dopamine Transporter peptide with a KD of 2.4 x 10-8 in an affinity binding assay.Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

General description

ZooMAb antibodies represent an entirely new generation of recombinant monoclonal antibodies.Each ZooMAb antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb antibodies are reliably available and ready to ship when you need them.Learn more about ZooMAb here.

Immunogen

KLH-conjugated linear peptide corresponding to 18 amino acids from the N-terminal region of human Dopamine transporter.

Legal Information

ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany

Physical form

Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS with 5% Trehalose, normal appearance a coarse or translucent resin. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 µL.

Reconstitution

30 µg/mL after reconstitution at 25 µL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.

Specificity

Clone 1D2 is a ZooMAb rabbit recombinant monoclonal antibody that specifically detects Dopamine transporter. It targets an epitope within 18 amino acids from the N-terminal region.

Storage and Stability

Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 µL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.

Target description

Sodium-dependent dopamine transporter (UniProt: Q01959; also known as DA transporter, DAT, Solute carrier family 6 member 3) is encoded by the SLC6A3 (also known DAT1) gene (Gene ID: 6531) in human. Dopamine transporter is a multi-pass membrane protein with one extracellular domain (aa 161-237), two cytoplasmic domains (aa 1-68 and 589-620), and twelve transmembrane domains. It serves as an sodium/chloride-dependent amine transporter protein that pumps dopamine out of the synaptic cleft back into cytosol and terminates the effects of dopamine. It is shown to be highly expressed in substantia nigra. The dopamine transporter has been a target of several drugs, including psychostimulants, such as amphetamine and cocaine and is also subject to short- and long-term regulation by several drugs and mechanisms. Mutations in SCL6A3 gene are known to cause Infantile Parkinsonism-dystonia that is characterized by infantile onset of parkinsonism and dystonia along with global developmental delay and bradykinesia. Mice deficient in dopamine transporter exhibit reduced bone mass due to diminished cancellous bone volume, increased trabecular spacing, and reduced trabecular volume. This ZooMAb recombinant monoclonal antibody, generated by our propriety technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals.